A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
SARASOTA, Fla., March 22, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, announced today that Inger...
SARASOTA, Fla., March 10, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell®, an advanced fertility treatment technology which is currently available through a number of channels, including its new joint-venture owned INVO Center in...
Tampa INVO Center to focus on advanced fertility care utilizing INVOcell®SARASOTA, Fla. and TAMPA, Fla., Feb. 16, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with...
SAN FRANCISCO, CA / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care. INVO Bioscience...
Focused on addressing underserved patients within the fertility marketplaceSARASOTA, Fla., Feb. 3, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ("INVO"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with...
Agreement follows initial utilization of INVOcell by Ovoclinic phyisicians in early 2021, resulting in successful patient experiences and outcomesOvoclinic will expand use of INVOcell in all four of their clinics and become the Center of Excellence and Training Site...
During this fireside chat we welcome INVO Bioscience, ticker symbol of INVO on the NASDAQ and their CEO, Mr. Steve Shum. INVO is a healthcare services fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility...
SARASOTA, Fla., Dec. 10, 2021 -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, announced today that it will be participating in the Lytham Partners Winter 2021...
INVO's distribution partner, IVF Envimed Company Ltd., set to begin commercialization of the INVOcell system within Thailand.SARASOTA, Fla., Dec. 1, 2021 -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in...
Company to Host Conference Call Today at 4:30pm ET (Details Below)SARASOTA, Fla., Nov. 15, 2021 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a medical device company focused on creating alternative treatments for patients diagnosed with...